GlassScriptPhysician profile
Ashif K Jethava
NPI 1669632782
$2,482.63
in general payments reported to CMS, 2019-2025
20 companies · $673 in 2025
The $673 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $258 · 2021: $14.65 · 2022: $179 · 2023: $176 · 2024: $436 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,114 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.85 |
| Education | $170.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $546.66 | 2019-2025 | Jynarque, Voyxact |
| Akebia Therapeutics INC | $281.49 | 2019-2025 | Vafseo, Auryxia |
| Amgen INC. | $236.13 | 2019-2025 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $223.18 | 2023-2025 | |
| Travere Therapeutics, INC. | $178.05 | 2024-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $173.79 | 2019-2024 | Lokelma |
| Vifor Pharma, INC. | $162.42 | 2019-2024 | Veltassa |
| Fresenius USA Marketing, INC. | $146.98 | 2019-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $137.46 | 2019-2024 | Rayaldee |
| Calliditas Therapeutics US INC. | $88.11 | 2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.61 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $62.15 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $56.87 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $19.20 | 2022 | |
| Aurinia Pharma U.S., INC. | $17.88 | 2025 | Lupkynis |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.11 | 2025 | |
| Lilly USA, LLC | $16.99 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $15.87 | 2020 | |
| Genentech USA, INC. | $14.80 | 2025 | Gazyva |
| Horizon Therapeutics Plc | $12.88 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashif Jethava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.